<!DOCTYPE html>
<html>
	<head>
		<meta charset="UTF-8">
		<meta name="viewport" content="width=device-width, initial-scale=1">
		<title>Osteomyelitis: Spine</title>
		<link href="/index.css" type="text/css" rel="stylesheet">
		<script src="//code.jquery.com/jquery-1.10.2.js"></script>
		<script>
			$(function(){
				$("#header").load("/header.html");
				$("#footer").load("/footer.html");
			});
		</script>
		<script>
			function navDrop() {
				var x = document.getElementById('navlinks');
				if (x.style.display === 'flex') {
					x.style.display = 'none';
				} else {
					x.style.display = 'flex';
				}
			}
		</script>
	</head>
	<body>
		<header id="header"></header>
		<div class="spacer"></div>
		<div class="main">
			<h1>Osteomyelitis</h1>
			<h2 id="anatomical-approach">Anatomical Approach</h2>
			<h3 id="spine">Spine</h3>
			<h4 id="native-vertebral-osteomyeletis">Native Vertebral Osteomyeletis</h4>
			<h5 id="etiology">Etiology</h5>
			<p>Occurs mainly due to hematogenous seeding of disc from a distant focus.</p>
			<h5 id="microorganisms">Microorganisms</h5>
			<p>Most common cause is <em>Staphylococcus aureus</em>. Other causes are enteric gram-negative bacilli, viridans streptococci-milleri group. streptococcus gallolyticus (bovis), enterococci, group B and group C streptococcus, <em>Pseudomonas aeruginosa</em>, coag negative staph.</p>
			<p>Candida species are seen in association with intravascular access, sepsis, or IV drug use, and esophageal performation.</p>
			<p>Tuberculosis, Brucellosis</p>
			<h5 id="clinical-features">Clinical Features</h5>
			<ul>
			<li><p>Back/neck pain that is worsened on movement and physical activity. Can radiate to abdomen, groin, perineum, arms.</p></li>
			<li><p>The pain can be associated with radicular symptoms, including numbness, tingling, paresthesias.</p></li>
			<li><p>Sometimes, it can lead to loss of bowel and bladder control, loss of perineal sensation, and paralysis.</p></li>
			<li><p>Fever.</p></li>
			</ul>
			<h5 id="diagnosis-2">Diagnosis</h5>
			<ul>
			<li><p>Appropriate history, such as IV drug use, recent bacteremia, recent dental work, trauma, previous vertebral osteomyelitis with neurological exam example decreased sensations, decreased sphincter tone, hyperreflexia.</p></li>
			<li><p>Baseline ESR and CRP-Increased ESR; CRP is not specific but has a sensitivity of 94–100%.</p></li>
			<li><p><strong>MRI spine</strong>.</p></li>
			<li><p>If MRI of the spine is not possible, recommend radionucleotide bone scan, CT scan, or positron emission tomography scan.</p></li>
			<li><p>Blood cultures.</p></li>
			<li><p>Patients from <strong>endemic areas</strong> (e.g., from Mediterranean basin)—Brucellosis serology, PPD, or interferon gamma release assay for patients at risk.</p></li>
			<li><p>Image-guided biopsy is recommended when a microbiologic diagnosis for a known associated organism has not been established by blood cultures or serologic tests.</p></li>
			</ul>
			<h5 id="treatment-2">Treatment</h5>
			<ul>
			<li><p>Empiric therapy <strong>should be deferred</strong> until an image-guided aspiration and/or biopsy of the affected area is performed.</p></li>
			<li><p>Empiric therapy <strong>should not be deferred</strong> in life-threatening conditions, such as sepsis or impending spinal cord or nerve root compression (in these situations, may require adjective steroids).</p></li>
			<li><p><strong>Empiric therapy</strong> directed against methicillin-resistant S. aureus(MRSA), streptococci, and gram-negative organisms, e.g. IV vancomycin and third or fourth generation cephalosporin/ ciprofloxacin/ carbapenem. Alternative regimen: combination of daptomycin and a quinolone.</p></li>
			</ul>
			<p><span class="h6" id="pathogen-directed-therapy">Pathogen-directed therapy:</span> see <strong>Table <a href="#nativevertebralosteomyelitis" data-reference-type="ref" data-reference="nativevertebralosteomyelitis">1</a></strong>.</p>
			<hr/>
			<div class="table">
			<table style="width: 1024px;">
				<caption><strong>Table 1.</strong> Pathogen-directed therapy for native vertebral osteomyelitis.</caption>
				<thead>
					<tr class="header">
						<th>Microorganism</th>
						<th>First Choice</th>
						<th>Alternatives</th>
						<th>Comments</th>
					</tr>
				</thead>
				<tbody>
					<tr class="odd">
						<td>Staphylococci, oxacillin-susceptible</td>
						<td>IV Nafcillin sodium or oxacillin 1.5–2 g IV q4–6 h or continuous infusion<br>IV Ceftriaxone 2 g IV q12h/24h</td>
						<td>Vancomycin IV 15–20 mg/kg q12 h or daptomycin 6–8? mg/kg IV q24 h? or linezolid 600 mg PO/IV q12 h or levofloxacin 750 mg PO q24 h PLUS rifampin PO 600 mg daily or clindamycin IV 600–900 mg q8 h<br>Oritavancin<br>Dalbavancin</td>
						<td>6-week duration</td>
					</tr>
					<tr class="even">
						<td>Staphylococci, oxacillin-resistance</td>
						<td>Vancomycin IV 15–20 mg/kg q12 h</td>
						<td>Daptomycin 6–8 mg/kg IV q24 h or linezolid 600 mg PO/IV q12 h or levofloxacin PO 500–750 mg PO q24 h and rifampin PO 600 mg daily<br>Oritavancin 1200 mg IV over 3 hours single dose<br>Dalbavancin</td>
						<td>6-week duration</td>
					</tr>
					<tr class="odd">
						<td>Enterococcus species, penicillin-resistant</td>
						<td>Vancomycin IV 15–20 mg/kg q12 h</td>
						<td>Daptomycin 6 mg/kg IV q24 h or linezolid 600 mg PO or IV q12 h<br>Oritavancin<br>Dalbavancin</td>
						<td></td>
					</tr>
					<tr class="even">
						<td><em>Pseudomonas aeruginosa</em></td>
						<td>Cefepime 2 g IV q8–12 h or meropenem 1 g IV q8 h or doripenem 500 mg IV q8 h</td>
						<td>Ciprofloxacin 750 mg PO q12 h (or 400 mg IV q8 h) or aztreonam 2g IV q8 h for severe penicillin allergy and quinolone-resistant strains or ceftazidime 2 g IV q8 h</td>
						<td>6 wk duration. Double cover- age may be considered (i.e., beta-lactam and ciprofloxacin or beta-lactam and an amino- glycoside)</td>
					</tr>
					<tr class="odd">
						<td>Enterobacteriaceae</td>
						<td>Cefepime 2 g IV q12 h or ertapenem 1 g IV q24 h</td>
						<td></td><td></td>
					</tr>
				</tbody>
			</table>
			</div>
			<!-- <span class="h6" id="adjuvant-treatments">Adjuvant treatments</span>-->
			<p><span class="h6" id="duration-of-therapy">Duration of therapy:</span></p>
			<ul>
				<li><p>Total duration of 6 weeks of parenteral or highly bioavailable oral antimicrobial therapy for most patients with bacterial NVO.</p></li>
				<li><p>Total duration of 3 months of antimicrobial therapy for most patients with NVO due to Brucella species.</p></li>
			</ul>
			<p><span class="h6" id="when-to-do-surgery">When to do surgery:</span></p>
			<ul>
				<li><p>Progressive neurologic deficits, progressive deformity, and spinal instability with or without pain despite adequate antimicrobial therapy.</p></li>
				<li><p>Patients with persistent or recurrent bloodstream infection (without alternative source) or worsening pain despite appropriate medical therapy.</p></li>
				<li><p>Large epidural abscess.</p></li>
				<li><p>No need surgical debridement and/or stabilization in patients who have worsening bony imaging findings at 4–6 weeks in the setting of improvement in clinical symptoms, physical examination, and inflammatory markers.</p></li>
			</ul>
			<p><span class="h6" id="follow-up-therapy">Follow-up therapy:</span></p>
			<ul>
				<li><p>Persistent pain, residual neurologic deficits, elevated markers of systemic inflammation, or radiographic findings alone <strong>do not necessarily signify treatment failure</strong> in treated NVO patients.</p></li>
				<li><p>The most <strong>specific measure of treatment failure</strong> is <strong>microbiologically confirmed persistent infection</strong> despite receipt of targeted antimicrobial therapy for an appropriate duration.</p></li>
				<li><p>Monitoring systemic inflammatory markers <strong>(ESR and or CRP)</strong> after approximately 4 weeks of antimicrobial therapy, in conjunction with a clinical assessment.</p></li>
			</ul>
			<h4 id="spine-osteomyelitis-with-hardware">Spine osteomyelitis with hardware</h4>
			<h5 id="etiology-1">Etiology</h5>
			<p>Vertebral osteomyelitis in the presence of spinal hardware occurs usually in the presence of wound infection rather than hematogenous seeding.</p>
			<h5 id="microorganisms-1">Microorganisms</h5>
			<p>Most common pathogen is <em>S. aureus</em> (MRSA, MSSA), followed by coag-negative staph. Others: gram negative organisms and anaerobes.</p>
			<h5 id="clinical-signs">Clinical signs</h5>
			<p>Fever, worsening back pain, neuropathic pain. Severe symptoms are stool/urine incontinence, paralysis, or even death.</p>
			<h5 id="antibiotic-and-surgical-management">Antibiotic and surgical management</h5>
			<p>Decision regarding surgical management should be made by the orthopedic surgeon with appropriate consultation.</p>
		</div>
		<footer id="footer"></footer>
	</body>
</html>